Learn More
A major obstacle in performing multicenter controlled trials for pemphigus is the lack of a validated disease activity scoring system. Here, we assess the reliability and convergent validity of the PDAI (pemphigus disease area index). A group of 10 dermatologists scored 15 patients with pemphigus to estimate the inter- and intra-rater reliability of the(More)
BACKGROUND Most patients with psoriasis have nail changes, and treating nail psoriasis is challenging. OBJECTIVES To assess improvement in fingernail psoriasis with ustekinumab treatment in the PHOENIX 1 trial. METHODS Patients received ustekinumab 45 mg or 90 mg, or placebo at weeks 0 and 4. Ustekinumab-randomized patients continued maintenance dosing(More)
BACKGROUND An unmet need remains for safe and effective long-term treatments of psoriasis. OBJECTIVES To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 trial. METHODS Patients (n = 766) with moderate-to-severe psoriasis were randomized to ustekinumab 45 mg or 90 mg at weeks 0 and 4, and then every 12 weeks, or placebo at(More)
BACKGROUND Psoriasis is associated with several comorbidities and behavioural risk factors. OBJECTIVES To evaluate demographic and disease characteristics in patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). METHODS PSOLAR is a global, prospective, longitudinal, disease-based registry that includes a postmarketing(More)
BACKGROUND Drug survival is a marker for treatment sustainability in chronic diseases such as psoriasis. OBJECTIVE The aim of these analyses was to assess survival of biologic treatments in the PSOriasis Longitudinal Assessment and Registry (PSOLAR). METHODS PSOLAR is a large, prospective, international, disease-based registry of patients with psoriasis(More)
BACKGROUND Phase 3 studies showed some patients maintained response for ≥6 months post-ustekinumab discontinuation. OBJECTIVES To assess clinical responses with extended ustekinumab maintenance dosing intervals. METHODS Adults with moderate-to-severe plaque psoriasis received ustekinumab (45mg/90mg for weight ≤100 kg/>100 kg) at Week0, Week4, Week16(More)
  • 1